Amylyx Pharmaceuticals, Inc.
AMLX
Classificação em ações
#4491
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Preço da ação
$27.25
Última sincronização: 2026-10-19
Valor de mercado
$3.42B
Variação (1 dia)
3.45%
Variação (1 ano)
77.29%
País
US
Negociar Amylyx Pharmaceuticals, Inc. (AMLX)
Categoria
Healthcare
Rácio P/S de Amylyx Pharmaceuticals, Inc. (AMLX)
Rácio P/S em October 2026 TTM: 0.00
De acordo com os relatórios financeiros mais recentes e o preço das ações da Amylyx Pharmaceuticals, Inc., o rácio P/S atual (TTM) é 0.00. No final de 2023, o rácio P/S era 2.60.
Histórico do rácio P/S da Amylyx Pharmaceuticals, Inc. de 2019 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 2.95 | 13.43% |
| 2023 | 2.60 | -97.65% |
| 2022 | 110.55 | -96.99% |
| 2021 | 3.67K | 133.72% |
| 2020 | 1.57K | 119.38% |
| 2019 | 715.53 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
